Gapping up
In reaction to earnings/guidance:
- RADA +8.2% (guides 2021 revenue above consensus), NKE +6%, FDS +1.4%,
M&A news:
- AJRD +26.5% (to be acquired by Lockheed Martin Corporation (LMT) in an all-cash transaction with a total equity value of $5.0 bln or $56.00/share)
- MNR +4.8% (approached by Blackwells)
Select financial related names showing strength:
- JPM +3.9% (intends to maintain its dividend of $0.90/sh for Q1; co has also authorized a new $30 bln share repurchase program, co intends to begin share repurchases in Q1 )
- MS +3.2% (to resume repurchases of common stock in the first quarter of 2021)
- C +2.9% (plans to resume stock repurchases in Q1 )
- BK +1.7% (expects to maintain dividend and resume stock repurchases)
- WFC +1.4% (Comments on Federal Reserve's Stress Test Results; co is allowed to pay dividends and make share repurchases)
Other news:
- MYOV +2.7% (announces FDA approval of ORGOVYX as treatment for adult patients with advanced prostate cancer )
- ONE +1.4% (restructures investment portfolio of small-class business to focus on premium personalized tutoring business)
- OTIC +1.1% (announces initiation of expansion cohorts in phase 1b study of ORIC-101)
- MRNA +0.8% (announced that the FDA has authorized the emergency use of mRNA-1273, Moderna's vaccine against COVID-19 in individuals 18 years of age or older)
Analyst comments:
- RPT +3.7% (upgraded to Neutral from Underweight at JP Morgan)